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Interleukin-8 and polymorphoneutrophil leucocyte activation in hemo-
lytic uremic syndrome of childhood. Polymorphoneutrophil leucocytes(PMNLs) are implicated in the pathogenesis of diarrhea-associated
hemolytic uremic syndrome (D+ HUS). We investigated mechanisms
of PMNL involvement by measuring tumor necrosis factor a (TNFa)
and the novel cytokine, interleukin-8 (IL-8), a potent activator of
neutrophils, together with al- antitrypsin-complexed elastase (al-
AT-E) as a marker of neutrophil degranulation, and anti-neutrophil
cytoplasmic antibodies (ANCA). IL-8 was not detected in the 17 normal
children, but was significantly elevated in 20 of 25 D+ HUS children (P
< 0.005), and in three of nine children with non-diarrhea-associated
(D—) HUS. Sequential data showed that IL-8 peaked transiently in the
circulation, reaching a maximum just before a more protracted burst of
al-AT-E. The IL-8 levels correlated significantly with circulating
aI-AT-E concentrations (r = 0.50, P <0.05). In D+ HUS IL-8 levels
also correlated with the PMNL count (r = 0.63, P < 0.005), and the
highest values were seen in those children who died in the acute phase
of the disease. TNFa was raised in only I of 16 D+ HUS children and
in no patients were ANCA detected. The data suggest that PMNLs in
HUS are recruited by IL-8, that this cytokine plays a key role in the
PMNL activation which occurs, and that agents which suppress this
recruitment and activation might play a therapeutic role in this disorder.
There is now substantial evidence pointing to PMNL involve-
ment in the pathogenesis of D+ HUS. This disorder, which is
the most common cause of acute renal failure in children in the
United Kingdom, is characterized by hemolytic anemia, throm-
bocytopenia and renal failure [1, 2]. Two broad subtypes are
recognized: the first is associated with diarrheal prodrome (D+)
whereas the second, which is rare in childhood and has a worse
prognosis, is not (D—) [2]. The peripheral blood PMNL count is
raised at presentation in D+ HUS [3], and there is an associa-
tion between the height of the PMNL count, acute mortality,
and residual nephropathy [3—6]. There is evidence that acti-
vated PMNLs cause endothelial injury [7—9] and that their
release products can damage the glomerular basement mem-
brane [101. In D+ HUS children, PMNLs have been found to
adhere more avidly to endothelium and to damage the endothe-
hal cell [11], and alpha 1-antitrypsin complexed elastase (al-
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AT-E) levels are raised at presentation, reflecting PMNL acti-
vation and degranulation [12].
The aim of the present study was to investigate mechanisms
of PMNL involvement by measuring mediators and markers of
PMNL activation in the serum and plasma of children with D+
HUS. We measured two key participants in the cytokine
cascade: tumor necrosis factor a (TNFa) and interleukin 8
(IL-8). TNFa is a proinflammatory cytokine and a proximal
mediator in the cascade having the ability to induce gene
expression for other cytokines and receptors such as IL-i, IL-6,
IL-2 receptor and IL-8 [13, 14]. IL-8 is a cytokine which is
produced by monocytes and is primarily defined as a selective
activator and chemoattractant of PMNLs; it stimulates the
release of lysosomal enzymes and superoxides from them [15].
In this study we investigated whether IL-8 was released into
serum in the acute phase of D+ HUS and its relationship to
peripheral blood PMNL count; we measured PMNL aI-AT-E
which is a marker of PMNL degranulation [16—18] and anti-
neutrophil cytoplasmic antibody (ANCA) which is present in
other vasculopathies [19—22].
Methods
Patients
Thirty-four children with HUS treated at the Hospital for
Sick Children, Great Ormond Street, London, were studied.
The criteria for diagnosis were a microangiopathic hemolytic
anemia, thrombocytopenia, and acute renal failure. They were
divided into two groups on the basis of the presence (D+ HUS;
N = 25) or absence (D— HUS; N = 9) of a diarrhea! prodrome.
Three of the children with D+ HUS died within four days of
admission to the Unit. Blood samples were taken within 24
hours of admission, and nine children also had serial samples
taken throughout the acute phase of their illness.
Blood samples were also obtained from: (1.) seventeen
healthy control children admitted for routine surgical proce-
dures or investigation of short stature; and (2.) fifteen sick
children identified by the hematology laboratory as having a
PMNL count >10 x 109/liter, designated high PMNL count
controls, they had a septicemia or other infection, and all had a
normal plasma creatinine concentration. Blood samples were
obtained from them within 48 hours of admission. (3.) Ten
children with chronic renal failure were included, all of whom
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Fig. 1. JL-8 standard curve - plotting IL-8 concentration (pg/mi)
against optical density (OD). The minimum detectable dose of IL-8 is
50 pg/mI.
who had a glomerular filtration rate (GFR) less than 15 ml/min/
1.73 m2 SA.
Samples
Blood samples were collected for measurement of IL-8,
TNFa, and ANCA into plain tubes with no anticoagulant and
for al-AT-E into potassium EDTA (ethylenediaminetetraacetic
acid) tubes. The samples were separated by centrifugation at
2000 g within 30 minutes, and serum and plasma were stored at
—70°C until assayed.
Methods
Serum IL-8 immunoassay
IL-8 was measured by solid phase enzyme linked immunoas-
say (ELISA; Quantikine, Research and Diagnostic Systems,
Minneapolis, Minnesota, USA). A monoclonal antibody spe-
cific for IL-8 was coated onto the microtiter plates provided.
Standards with known amounts of IL-8 and samples were
pipetted, in duplicate, into the wells, and any IL-8 present
bound by the immobilized antibody. For detection, an enzyme-
linked polyclonal antibody specific for IL-8 was applied. A
substrate solution containing tetramethylbenzidine and H202
was added, and the color developed was proportional to the
amount of IL-8 bound in the initial step. A standard curve was
drawn of optical density (OD) against IL-8 concentration (Fig.
1). The lower limit of detection in this assay was 50 pg/mI. This
was determined by adding 2 standard deviations to the mean
optical density value of 5 zero standard replicates and calculat-
ing the corresponding concentration from the standard curve.
The intra-assay coefficient of variation (CV) was 8% (N = 10)
and the interassay CV was 9.3% (N = 5).
Serum TNFa immunoassay
TNFa was measured by solid phase ELISA (Quantikine). A
monoclonal antibody specific for TNFa was coated onto the
microtiter plates provided. Standards with known amounts of
TNFa and samples were pipetted, in duplicate, into the wells.
For detection, an enzyme-linked polyclonal antibody specific
for TNFa was applied. A substrate solution was added, as
above, and a standard curve drawn of OD against the concen-
tration of TNFa in the standard wells. The lower limit of
detection for this assay was 10 pg/mI. The intra-assay CV was
5.4% (N = 10) and inter-assay CV 4% (N = 5).
Human al-AT complexed elastase immunoassay
Plasma al-AT-E was measured by a modified ELISA as
previously described [121. A sheep anti-human elastase anti-
body (ICN Immunobiologicals, High Wycombe, UK) specific
for leucocyte elastase was coated onto microtiter plates (Nunc,
Roskilde, Denmark). For detection, horseradish-peroxidase-
conjugated sheep anti-human al-AT (The Binding Site Ltd.,
Birmingham, UK) was applied. A substrate was added and the
color developed in proportion to the amount of al-AT corn-
plexed elastase bound in the initial step. Standards were ob-
tained by adding increasing amounts of human elastase (Sigma,
Poole, Dorset, UK) to a constant volume of control plasma,
giving final elastase concentrations of 50 to 16,000 ng/ml. A
standard curve was prepared of OD versus al-AT complexed
elastase in the standard wells and by comparing the OD of the
samples to the standard curve of the concentration of al-AT
complexed elastase in the unknown samples determined.
Immunoassay for ANCA against an acid extract of neutrophil
cytoplasm
1gM and IgG ANCA were measured in serum by an ELISA
technique using acid extracted neutrophil cytoplasm antigen
prepared as described by Savage et al [231. For each prepara-
tion, the optimal dilution for coating was determined using
negative control sera and positive patient sera. The antigen was
coated onto microtiter plates (Nunc). Test or control serum
samples were added in duplicate to neutrophil antigen-coated
plates. For detection, peroxidase conjugated anti-human IgG
and 1gM (Sigma) were applied, and after incubation and wash-
ing a substrate was added. After further incubation the reaction
was stopped and ODs measured using an ELISA reader. The
OD values of the standard sera at various dilutions were used to
construct a standard curve of arbitrary units, from which the
ANCA content of each test serum could be estimated. The
arbitrary units were set as 64 and 32 for the IgG class ANCA-
positive standard serum and 1gM class ANCA-positive standard
serum, respectively. The normal range for 1gM for this assay is
0.5 to 9.1 units and for IgG 0.5 to 9.0 units.
Statistical analysis
Fisher's Exact test was used to determine the significance of
the IL-8 results in the different groups compared to normals.
The Mann-Whitney test was used as a test of significance of
difference between the medians of the different groups. The
correlations between IL-8 and al-AT-E, and IL-8 and PMNL
count were examined non-parametrically using Spearman's
rank correlation coefficient. al-AT-E and PMNL counts were
log-normally distributed, and geometric means were compared
using Student's t-test on log-transformed data.
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Results
Serum IL-8
IL-8 was not detected in the serum of 17 normal healthy
children. It was, however, detected and was significantly ele-
vated in 20 of 25 children with D+ HUS [median value: 305
pg/ml, range: non-detectable (ND) - 3300, P <0.0051, and in
three of nine D— HUS children (P < 0.05; Fig. 2). The median
IL-8 value in D+ HUS was significantly higher than in D— HUS
(P < 0.005). Only two of ten children in chronic renal failure
(CRF) had detectable IL-8 levels, and this did not reach
significance (P > 0.05). Children in the high PMNL control
group had significantly elevated IL-8 with a median value of 460
pg/mi (range 150 to 5200, P < 0.005), and these results were not
significantly different from those obtained in the D+ HUS
group (P> 0.05).
Serum TNFc
When 40 normal donor sera were evaluated using this assay
(Quantikine) the maximum observed value was 25.8 pg/mi.
TNFa was detected in the serum of only 1 of 16 of the children
with D+ HUS, in whom the level was 1800 pg/mI. Moderately
elevated levels were detected in three of 15 high PMNL
controls with values of 27, 28, and 30 pg/mi recorded, and no
significant activity was detected in any of the normal children or
those with D— HUS.
Serum ANCA
No 1gM ANCA was detected in any of the 10 D+ HUS or 9
D— HUS sera tested. One of the D— HUS group had a weakly
positive IgG ANCA of 13.1 units; the remaining 8 D— and all
the D+ HUS children had negative IgG ANCA results.
Serial IL-8 and al-AT-E
Serial measurements of IL-8 were undertaken in nine chil-
dren with D+ HUS following their admission in acute renal
failure, and in seven of them al-AT-E was also measured. This
data is graphically illustrated in Figures 3 and 4. In this group of
patients the serum IL-8 reached a maximum on day 3 with a
mean of 8,193 pg/mI, and then fell sharply to mean values of 272
and 312 pg/mI on days 4 and 5, respectively. al-AT-E peaked
on days 3 to 4 with mean values of 5,100 and 4,200 ng/ml,
respectively, but then declined more gradually. The highest
values for both IL-8 and al-AT-E were seen in the three
children who died in the acute phase of the disease (Figs. 2 and
3). We found a significant positive correlation between the IL-8
and the circulating al-AT-E levels (r = 0.50, P < 0.05) in these
children.
Polymorphoneutrophil leucocyte counts (PMNLs)
The children with D+ HUS had a raised PMNL count at
presentation with a geometric mean of 14.0 x 109/iiter (range
7.6 to 24.3). Their mean PMNL count was significantly higher
than the PMNL count of 4.9 x 109/liter (2.7 to 6.8) in normal
controls (P < 0.001) and 5.7 x l09/liter (4.6 to 7.2) in D— HUS
(P < 0.001). Serial PMNLs on eight of the nine patients are
illustrated in Figure 5; they remain elevated over a longer
period than both the IL-8 and the cil-AT-E, returning gradually
into the normal range by days 11 to 12.
There was a significant positive correlation between the
PMNL count and the IL-8 level at presentation in the D+ HUS
group (r = 0.63, P < 0.005), but not in the high PMNL group (r
= 0.34, P > 0.05).
Discussion
The etiology of D + HUS is more clearly understood now that
an association has been found with toxin-producing enteric
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Fig. 2. !L-8 concentrations in D+ HUS, D— HUS, high polymorpho-
neutrophil leucocyte (PMNL) count controls and chronic renal failure
(CRF). The dotted line corresponds to the minimum detectable dose
and all points below this line represent undetectable levels.
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Fig. 3. Serial IL-8 levels (pg/mi) in 9 children with D+ HUS following
admission.
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Fig. 7. IL-8 levels and peripheral blood polymorphoneutrophil leuco-
cyte (PMNL) counts in D+ HUS (•; r = 0.63; P = 0.002) and high
PMNL count controls (A; r = 0.34; P = 0.21).
has an important role in the pathogenesis. There is a significant
relationship between the PMNL count at onset and adverse
outcome [3—6]. HUS PMNLs show increased adhesion to
endothelium in vitro [11], al-AT complexed elastase levels are
increased in the acute phase of the syndrome [12], and by
electron microscopy peripheral blood neutrophils appear de-
granulated [261.
It is not known whether the neutrophil response which occurs
is attributable to the action of verocytotoxin or to endotoxin,
the lipopolysaccharide (LPS) derived from the bacterial cell
10 12 wall. Endotoxin has been suggested as having a pathogenic role
in D+ HUS but has not yet been studied in YTEC disease. It
alters the surface characteristics of endothelial cells via a
cascade of cytokines which renders them adhesive for neutro-
phils [27, 28].
Significant TNFa was detected in only one of the 16 D+ HUS
children tested; this child was admitted in the early phase of her
disease before the onset of acute renal failure. She subsequently
went into renal failure and developed neurological complica-
tions. She survived her acute illness but has residual nephrop-
athy with proteinuria and a reduced GFR. TNFa is a proximal
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Fig. 4. Serial plasma al-antitrypsin complexed elastase levels (xg/ml)
in 7 children with D+ HUS following admission.
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Fig. 5. Serial peripheral blood polymorphoneutrophil leucocyte
(PMNL) counts in 8 children with D+ HUS following admission.
pathogens, in particular Verocytotoxin-producing Escherichia
coil (VTEC) [24, 25]. It is also well recognized that damage to
the glomerular endothelium is the main site of injury in HUS,
and there is now increasing evidence suggesting that the PMNL
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mediator in the cytokine cascade, appearing in the circulation of
several species as a brief, early peak after infusion of bacteria or
bacterial LPS [13]. The majority of our patients were referrals
from other hospitals admitted to the unit several days after the
onset of their illness, which may account for our inability to
detect TNFa in the others at the time of their admission.
IL-8 is a recently described 6-10 kDa protein known for its in
vitro leucocyte chemoattractant and activation properties [29—
36], and is a potential mediator of host response to injury and
infection. It has several properties that suggest that it plays a
role in mediating some of the inflammatory responses of neu-
trophils induced by endotoxin, IL-i and TNFa [151. It is known
to cause shedding and up-regulation, respectively, of the two
important neutrophil adhesion molecules: leucocyte adhesion
molecule 1 (also known as LAM-i, LECAM-i and L-selectin)
and CD11b/CD18 [37—39]. Adherence via the latter has been
shown to mediate neutrophil priming for the respiratory burst
[40] and degranulation [41]. It has been shown that IL-8 appears
in the circulation of primates in vivo during septic shock,
sublethal endotoxemia, and after the administration of IL-la
[42]; more recently increased levels have been detected in
normal humans as part of the acute inflammatory response to
intravenously administered endotoxin [43].
We detected significantly elevated IL-8 in both D+ and D—
HUS and in high PMNL controls. IL-8 levels were significantly
higher in D+ than in D— HUS. Our study therefore demon-
strates that IL-8 is produced in vivo as part of the inflammatory
response occurring in humans during the acute phase of D+
HUS. The sequential data on nine children with D+ HUS
shows that IL-8 circulates in blood with peak levels occurring at
72 hours.
Serial measurements of al-AT-E, a known marker of PMNL
activation and degranulation [16-18], were undertaken on seven
of the nine patients. Plasma al-AT-E levels peaked at 72 to 96
hours and declined more slowly than the corresponding IL-8
levels. From this data IL-8 appears to peak more transiently in
the circulation, achieving a maximum level just before the more
protracted burst of complexed elastase. The correlation of IL-8
with al-AT-E suggests that IL-8, which is known to stimulate
degranulation of adherent neutrophils, may be promoting the
release of this proteolytic enzyme in these patients. A positive
correlation was also found between IL-8 and the PMNL count
at presentation in the D+ HUS group. This correlation is of
particular importance when considering that the outcome is
associated with the PMNL count at presentation [3—6], and
indeed the higher levels of IL-8 were recorded in three patients
who died during the acute phase of the disease.
From our data we cannot conclude whether the observed
release of IL-8 into serum in D+ HUS is induced by Verocy-
totoxin or high LPS levels. It is also unknown whether serum
IL-8 represents a pathogenetically important mechanism or is a
concommitant marker of disease activity. There is, however,
increasing evidence suggesting that IL-8 promotes leucocyte
adhesion in vivo and leads to recruitment of PMNLs to sites of
tissue inflammation [37, 38]. IL-8 has previously been shown to
induce granulocytosis upon systemic injection and skin reacton
upon local injection in experimental animals [44]. The recruit-
ment of PMNLs to inflammatory sites is also dependent on
other chemotactic factors generated in tissue, such as the
cleavage products of complement activation C5a and C3b,
which we are currently measuring prospectively in children
with HUS. Elevated elastase levels do indicate that granulo-
cytes become highly activated in this disease and may represent
a source of endothelial cell damage. Our findings in this study
are consistent with the hypothesis that IL-8 contributes to the
dynamics of circulating PMNLs and acts as a mediator of the
PMNL activation which occurs. We conclude that IL-8 partic-
ipates in the complex cascade of cytokine responses to infec-
tious and inflammatory stimuli, and plays a significant role in
the pathophysiology of D+ HUS. These findings raise the
possibility that agents which suppress PMNL recruitment and
activation may have a therapeutic role in this disorder.
We were unable to detect significant ANCA activity in HUS
serum and conclude that this antibody is not implicated in this
disease.
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